DOTATATE与FDG-PET互补分子代谢表征脑膜瘤:推进治疗计划与预后
本文报道一例67岁男性颅内WHO III级间变性脑膜瘤,术后放疗后25个月复发,行FDG与Ga-DOTATATE PET/MR评估生长抑素受体表达以指导治疗。扫描显示摄取一致与不一致区域,提示高SSTR2表达可能与代谢率增高区域不重合。
要点
- Ga-DOTATATE成像用于脑膜瘤,正日益用于筛选可能获益于靶向治疗(如Lu-DOTATATE)的患者。
- 本例为67岁男性WHO III级间变性脑膜瘤,术后调强放疗后25个月复发。
- FDG与Ga-DOTATATE PET/MR显示一致与不一致摄取区域,提示高SSTR2表达可能与代谢率增高区域不重合。
核心结论
- 高SSTR2表达可能与代谢率增高区域不重合。
研究设计与样本
- 本文为一例67岁男性颅内WHO III级间变性脑膜瘤的病例图像报告。
主要发现
- 患者行肿瘤切除术后接受调强放疗,25个月后复发。
- 患者接受FDG与Ga-DOTATATE PET/MR以评估生长抑素受体表达并指导后续治疗。
- 扫描显示一致与不一致的摄取区域,提示高SSTR2表达可能与代谢率增高区域不重合。
临床怎么用
- Ga-DOTATATE成像用于脑膜瘤,正日益用于筛选可能获益于靶向治疗(如Lu-DOTATATE)的患者。
- FDG与Ga-DOTATATE PET/MR用于评估生长抑素受体表达并指导后续治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ga-DOTATATE imaging for meningiomas is gaining clinical use for selecting patients that may benefit from targeted therapy (eg, Lu-DOTATATE). We present an image of a 67-year-old man with an intracranial WHO grade III anaplastic meningioma. He underwent tumor resection followed by intensity-modulated radiation therapy but experienced a recurrence 25 months later. He received an F-(FDG) and Ga-DOTATATE PET/MR to evaluate for the presence of somatostatin receptor expression and guide subsequent treatment. The scans showed both concordant and discordant regions of uptake, indicating that high somatostatin receptor (SSTR2) expression may not coincide with areas of increased metabolic rate.
引用
- Dressen MS, Muthukrishnan A, Tragon TR, et al. Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication. Clin Nucl Med. 2019. PMID: 30371576. doi:10.1097/RLU.0000000000002328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。